Sangui BioTech Yields Revenues of over USD70,000 in Q1 2015 According to Preliminary Figures
October 07 2014 - 2:22PM
Business Wire
According to preliminary, unaudited figures Sangui BioTech
International, Inc. yielded revenues from royalties and product
sales of more than USD70,000 in the course of the first quarter of
its financial year 2015, ended September 30, 2014. In the fourth
quarter of the 2014 financial year (ended June 30, 2014) revenues
had amounted to USD43,729; in the first quarter of its financial
year 2014 (ended September 30, 2014) the company reported revenues
of USD26,527.
Sangui BioTech International, Inc.,
Revenue Development for the 2013 through
2015
Financial Years (per quarter)
Fin. Quarter USD 2013 Q1 20.549 2013 Q2 27.494 2013
Q3 33.388 2013 Q4 24.056 2014 Q1 26.527 2014 Q2 33.776 2014 Q3
29.438 2014 Q4 43.729 2015 Q1 (p) >70.000
Sangui BioTech International, Inc. ("SGBI") is a holding company
the shares of which are being traded on the OTCQB marketplace
(www.otcmarkets.com: SGBI) and the OTC markets of Berlin and
Hamburg-Hannover stock exchanges. Its purpose is to provide
financing and access to the capital markets for the enterprises of
the Sangui group. Sangui BioTech GmbH is a ninety percent
subsidiary of Sangui BioTech International, Inc.
Some of the statements contained in this news release discuss
future expectations, contain projections of results of operation or
financial condition or state other “forward-looking” information.
These statements are subject to known and unknown risks,
uncertainties, and other factors that could cause the actual
results to differ materially from those contemplated by the
statements. The forward-looking information is based on various
factors and is derived using numerous assumptions. Important
factors that may cause actual results to differ from projections
include, among many others, the ability of the Company to raise
sufficient capital to meet operating requirements. Words such as
“anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,”
“estimates,” and variations of such words and similar expressions
are intended to identify such forward-looking statements. Unless
required by law, the Company undertakes no obligation to update
publicly any forward-looking statements, whether as a result of new
information, future events or otherwise.
Sangui BioTechJoachim FleingPhone: +49 (179) 7963472Fax: +49
(2302) 915191e-mail: fleing@sangui.de
Sangui Biotech (CE) (USOTC:SGBI)
Historical Stock Chart
From Jan 2025 to Feb 2025
Sangui Biotech (CE) (USOTC:SGBI)
Historical Stock Chart
From Feb 2024 to Feb 2025